Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial ...
Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback